This 2022 narrative review explores the phenomenon of acquired G6PD deficiency, a condition where G6PD enzyme activity is reduced due to non-genetic factors. Unlike the hereditary form, acquired G6PD deficiency arises from biochemical mechanisms that inhibit the enzyme in specific clinical contexts. The review identifies conditions such as hyperaldosteronism, diabetes,
This 2023 study evaluates the long-term surgical burden in survivors of childhood cancer using data from the CCSS cohort, comprising 25,656 survivors diagnosed between 1970–1999 and 5,045 sibling controls. Over a median follow-up of 21.8 years, survivors underwent 28,202 major surgical procedures (≥5 years post-diagnosis under anesthesia) versus 4,110 among
This study explores the altered metabolism of pregnenolone in an aldosterone-secreting adrenal tumor and its adjacent adrenal tissue. The findings highlight changes in the steroidogenesis pathways of pregnenolone conversion to aldosterone and other steroid hormones, providing insights into the underlying mechanisms of hyperaldosteronism and adrenal tumors. The results could potentially
The article “Thyroid hormone resistance: Mechanisms and therapeutic development” explores thyroid hormone resistance syndrome (RTH), a condition caused by impaired thyroid hormone (TH) function due to mutations in thyroid hormone receptor β (TRβ) and, less commonly, thyroid hormone receptor α (TRα). Patients with RTH may exhibit goiter, mental retardation, short
This systematic review evaluates the safety of combining levothyroxine (LT4) and triiodothyronine (T3) for hypothyroidism treatment, particularly assessing the risk of thyrotoxicosis. Despite mixed evidence on clinical benefits, some patients report symptom improvement with LT4+T3 therapy. The review finds that safety concerns, especially regarding thyrotoxicosis, are minimal when LT4:T3 ratios
The article “Overt and subclinical hypothyroidism: who to treat and how” discusses the treatment strategies for overt and subclinical hypothyroidism, emphasizing that all patients with overt hypothyroidism and those with subclinical hypothyroidism with thyroid-stimulating hormone (TSH) levels exceeding 10 mIU/L should receive treatment. It highlights the importance of treating pregnant
The meta-analysis titled “Combined T4 + T3 Therapy Versus T4 Monotherapy Effect on Psychological Health in Hypothyroidism” (Clinical Endocrinology, 2022, PMID: 35445422) evaluated the psychological effects of combined levothyroxine (T4) and liothyronine (T3) therapy compared to T4 monotherapy across nine randomized controlled trials involving 1,210 hypothyroid patients. The analysis found
